A 3rd coronavirus vaccine works
Hello,Another Monday, another batch of
View all Offers
- 18% OFF
Redmi 9A (Nature Green, 2GB RAM, 32GB Storage) | 2GHz Octa-core Helio G25 Processor | 5000 mAh Battery₹ 6999₹ 8499Buy On
OnePlus Nord 2 5G (Blue Haze, 8GB RAM, 128GB Storage) I Extra upto Rs.1000 off on Exchange₹ 29999Buy On
OnePlus Nord 2 5G (Gray Sierra, 8GB RAM, 128GB Storage) I Extra upto Rs.1000 off on Exchange₹ 29999Buy On
- 19% OFF
Redmi Note 10 (Aqua Green, 4GB RAM, 64GB Storage) -Amoled Dot Display | 48MP Sony Sensor IMX582 | Snapdragon 678 Processor₹ 12999₹ 15999Buy On
- 18% OFF
Redmi 9A (Midnight Black 2GB RAM 32GB Storage) | 2GHz Octa-core Helio G25 Processor | 5000 mAh Battery₹ 6999₹ 8499Buy On
Meanwhile — the experimental antibody drug that President Donald Trump took as part of his COVID-19 treatment has received emergency use authorization, a step that could make it more widely available as cases continue to surge.Also today in
How the sprint for a coronavirus vaccine transformed Moderna into a $39 billion powerhouse that's poised to reshape biotech
- Moderna went from a hot biotech startup to one of the world's best-known companies, boosted most recently by its coronavirus-vaccine program.
- It says its shot is 94.5% effective at protecting people against COVID-19.
- While those results have yet to be published in a journal and regulators still need to review the data, the scientific feat outlines an exit plan from this pandemic.
- This is the inside story of how Moderna leveraged its speedy technology platform and ongoing research projects with the National Institutes of Health to develop an effective vaccine in record time.
- Now valued at $39 billion, the Massachusetts biotech is at the forefront of a revolution in vaccine research, driven by its promising technology.
- Vaccine research and development has improved massively throughout history.
- Nearly 200 years passed between the creation of the first successful vaccine and the eventual eradication of smallpox.
- The influenza virus was isolated in a lab in 1933, and the first flu vaccine wasn't licensed until 1945.
- Coronavirus vaccine research began just a few months after the first case of COVID-19 was observed, and it has progressed at a rapid pace.
Morgan Stanley predicts it will take 4 to 9 months to vaccinate the rest of the US after first responders and vulnerable people
- Two COVID-19 vaccines, one made by Moderna, another by Pfizer and BioNTech, announced promising results from their Phase 3 trials this week.
- Moderna announced that its vaccine was 94.5% effective on Monday, and Pfizer/BioNTech announced that their vaccine was 95% effective on Wednesday.
- Assuming that one or both of the vaccines receive emergency approval from the FDA, first responders and vulnerable populations will receive vaccines through March, a new analysis from Morgan Stanley predicts.
- After that, the rest of the US population will begin to be vaccinated, a process that Morgan Stanley predicts will take four to nine months.
More stories we're reading:
- Prenatal testing is leading to fewer births of people with Down Syndrome (The Atlantic)
- How the pharma giant Pfizer teamed up with a little-known biotech to develop an effective coronavirus vaccine in record time (Business Insider)
- People who develop COVID-19 antibodies are unlikely to get the virus again for at least 6 months, a new Oxford University study of more than 12,000 people suggests (Business Insider)
- Dr. Anthony Fauci: Santa has innate coronavirus immunity, so he won't be spreading COVID-19 (USA Today)
- Today is the last day of Rolex Rings’ ₹731 crore IPO with a price band of ₹880-900
- Punjab to bring Bill to earmark welfare budget for SCs in proportionate to their population
- High Pressure car washer price in India
- Best boAt headphones to buy in India
- Nothing ear (1) review – clean sound, transparent design for the win